Latest Regulatory Engagement News

Latitude Group Holdings Limited has launched an offer to raise approximately $100 million through Capital Notes 2, a new series of perpetual, subordinated, unsecured convertible notes. Existing Capital Notes 1 holders are invited to reinvest in the new notes, which feature discretionary quarterly distributions and potential conversion to ordinary shares.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

Lakes Blue Energy has temporarily halted gas flow testing at its Wombat-5 well to conduct extended pressure analysis, planning a perforation program to enhance production prospects.

Pancontinental Energy has won a crucial 12-month extension for its PEL 87 offshore Namibia exploration licence, enabling further seismic analysis and drilling preparations. This extension keeps the project on track as the company seeks a farmin partner to advance exploration.

Dimerix Limited is set to conduct a blinded statistical review of its pivotal Phase 3 ACTION3 study in March 2026, aiming to confirm the trial remains powered to demonstrate the primary endpoint of proteinuria reduction in FSGS patients.

Patrys has initiated manufacturing and regulatory steps for RLS-2201, its injectable Quetiapine formulation targeting delirium, aiming for Phase 0 trials in the second half of 2026.

Telix Pharmaceuticals has announced that Part 1 of its ProstACT Phase 3 trial for TLX591-Tx met its primary safety and dosimetry objectives, with no new safety concerns. The study’s success supports ongoing global enrolment in Part 2 and regulatory engagement in the US.

Native Mineral Resources has reported impressive shallow high-grade gold intercepts at its Podosky deposit, reinforcing plans to commence mining by April 2026. The results bolster confidence in the deposit’s open-pit potential and support ongoing development at the Ravenswood Gold Project.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Environmental Clean Technologies Limited reported a $2.58 million loss for the half-year ended December 2025, marking a strategic pivot with the acquisition of Terrajoule Pty Ltd and exclusive rights to innovative remediation technology.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

Patrys Limited reported a near doubling of its half-year loss to $3.02 million, driven by restructuring and a strategic pivot including the acquisition of Reliis Pty Ltd. The company is advancing a dual-platform biotech strategy combining a clinical-stage CNS asset with its proprietary antibody platform.